Trial Profile
Phase I/II Study of the Pharmacokinetics, Safety and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-Infected Children and Adolescents
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 13 Sep 2023
Price :
$35
*
At a glance
- Drugs Doravirine (Primary) ; Doravirine/lamivudine/tenofovir disoproxil fumarate (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacokinetics
- 10 Oct 2022 Results of PK and safety doravirine and doravirine/lamivudine/tenofovir disoproxil fumarate fixed dose combination , published in the JAIDS
- 20 Jun 2022 Status changed from active, no longer recruiting to completed.
- 17 Feb 2022 Planned End Date changed from 29 Dec 2021 to 1 May 2022.